Skip to main content

Filter Search Results

Publication Year

Animal Models

Topic Area

Methods

Funding Mechanism

Division of Comparative Medicine

Collaborating ICs

Selected Grantee Publications

Effect of Omeprazole on Esophageal Microbiota in Dogs Detected Using a Minimally Invasive Sampling Method

Handa et al., Journal of Veterinary Internal Medicine. 2025.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11864821

Omeprazole alters the esophageal microbiome (EM) of humans and has associated effects. The changes and subsequent recovery of the EM in 3- to 6-year-old dogs after omeprazole treatment were assessed using the esophageal string test (EST). All 10 dogs tolerated the EST without adverse effects, and the EST retrieved sufficient biofluid to characterize the EM. Diversity analysis revealed no significant alterations in alpha (Observed species, Shannon and Simpson indices) and beta diversity (Bray‐Curtis) across the time points after omeprazole administration. Thus, omeprazole therapy was not observed to alter the EM of healthy dogs in this study. The application of EST in dogs illustrates its use as a minimally invasive tool for investigating the role of EM in esophageal health and disease in dogs. Supported by ORIP (K01OD030515).

Single-Component Multilayered Self-Assembling Protein Nanoparticles Presenting Glycan-Trimmed Uncleaved Prefusion Optimized Envelope Trimers as HIV-1 Vaccine Candidates

Zhang, Nature Communications. 2023.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082823/

Researchers are interested in engineering protein nanoparticles to mimic virus-like particles for an HIV-1 vaccine. In this study, researchers explored a strategy that combines HIV envelope glycoprotein (Env) stabilization, nanoparticle display, and glycan trimming. They designed a panel of constructs for biochemical, biophysical, and structural characterization. Using female mice, female rabbits, and rhesus macaques of both sexes, they demonstrated that glycan trimming increases the frequency of vaccine responders and steers antibody responses away from immunodominant glycan holes and glycan patches. This work offers a potential strategy for overcoming the challenges posed by the Env glycan shield in vaccine development. Supported by ORIP (P51OD011133, P51OD011104, U42OD010442) and NIAID.